Latest Industry Insights

Explore the current understanding from the scientific literature on how protein misfolding, mislocalization and malfunction can lead to Alzheimer's disease.

As the use of generative AI tools expands, and their potential in scientific research is better understood, there are ethical considerations to be made. Dr. Dror Kolodkin-Gal explores some of the issues and potential solutions.

With growing sustainability demands, companies are looking for ways to demonstrate their green credentials. We spoke to Dr. Michael Frank to find out what ACT accreditation means for a company and why he thinks schemes like this are so important.

BetterLife Pharma’s lead candidate is a non-hallucinogenic derivative of LSD that mimics the projected therapeutic properties of LSD. To learn more, we spoke with BetterLife Pharma’s chief operating officer, Dr. Hooshmand Sheshbaradaran, and head of preclinical research, Dr. Abdi Ghaffari.

HPLC system manufacturers have been striving to improve usability, accessibility and help users improve their experimental outcomes. And what better way to do that than to involve the users themselves in that development process.

To learn more about the progress and development of non-hallucinogenic psychedelic therapies for conditions such as depression, Technology Networks spoke with the head of research and development at Delix Therapeutics, Dr. Eliseo Salinas.

We spoke to Prof. Oscar Ces, head of the Department of Chemistry at Imperial College London (ICL), to find out about the evolution of ICL’s White City Campus, the Agilent Measurement Suite and what it means for scientists across the board.

Technology Networks spoke with Dr. Sarah Inglis, trial manager of a recent study investigating the safety of a common ADHD medication, methylphenidate, in children and adolescents.

In this article, we explore how a future generation of scientists a century later took up Dr. Cajal’s call to arms and sought to counter his dire prognostication on the prospect of nerve regeneration.

In this interview, Technology Networks spoke to Dr. Stuart Marcus, founder and chief medical officer of SonALAsense, to find out how ALA sonodynamic therapy could be a more effective treatment for diffuse intrinsic pontine glioma and recurrent glioblastoma.